Contineum Therapeutics Amends ATM Program, Reports $19.6M in Recent Stock Sales, Expands Capacity to $100M
CTNM has more than doubled off its 52-week low of $3.35.
Summary
Contineum Therapeutics has amended its At-The-Market (ATM) offering program, reporting the sale of 3.24 million shares for $19.6 million and increasing the total potential offering size to $100 million, which will be used for R&D and general corporate purposes.
Key Events · Financing and Capital Events · CTNM
-
ATM Program Expanded and Amended
Contineum Therapeutics amended its Sales Agreement with Leerink Partners LLC, increasing the total capacity of its At-The-Market (ATM) offering program to $100 million. This is an update to an existing program established on May 14, 2025.
-
$19.6 Million in Shares Already Sold
As of March 5, 2026, the company has already issued and sold 3,241,110 shares under the Sales Agreement, generating gross proceeds of approximately $19.6 million.
-
Significant Potential Dilution
The remaining $80.4 million available under the ATM program, combined with the $19.6 million already sold, represents a substantial capital raise. If the full $100 million were sold at the assumed price of $15.34 per share, it would result in an immediate dilution of $7.18 per share for new investors, representing approximately 17.5% dilution to current outstanding shares.
-
Proceeds for R&D and General Corporate Purposes
The net proceeds from the offering are intended to advance the development of the LPA1R antagonist program (PIPE-791), fund other research and development activities, and cover general corporate purposes, including hiring and operating as a public company.
Analysis · CTNM · Life Sciences
Contineum Therapeutics, a clinical-stage biopharmaceutical company, has significantly expanded its At-The-Market (ATM) offering program, which is a critical financing mechanism for companies in this sector. The amendment increases the total potential capital raise to $100 million, a substantial amount relative to the company's market capitalization. The disclosure of $19.6 million in shares already sold under the program confirms active utilization of this facility. While securing capital is essential for funding ongoing research and development, particularly for the PIPE-791 program, the continuous issuance of shares through an ATM program creates an overhang on the stock and results in significant dilution for existing shareholders. If the full $100 million is sold, it represents a potential dilution of approximately 17.5% based on current outstanding shares, which is a material impact on per-share value.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 35.4% of the 1168 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTNM was trading at $13.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $504.5M. The 52-week trading range was $3.35 to $16.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.